Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses
暂无分享,去创建一个
[1] K S Crump,et al. Correlation between carcinogenic potency of chemicals in animals and humans. , 1988, Risk Analysis.
[2] B. Ames,et al. Too many rodent carcinogens: mitogenesis increases mutagenesis. , 1990, Science.
[3] J. Palacios,et al. α1-adrenoceptors in the mammalian brain: similar pharmacology but different distribution in rodents and primates , 1987, Brain Research.
[4] R. Maronpot,et al. Correlation of hepatocellular proliferation with hepatocarcinogenicity induced by the mutagenic noncarcinogen:carcinogen pair--2,6- and 2,4-diaminotoluene. , 1991, Toxicology and applied pharmacology.
[5] Gavin Kilpatrick,et al. Inter-species variants of the 5-HT3 receptor. , 1992, Biochemical Society transactions.
[6] D. Lowenthal,et al. Geriatric pharmacology: basic and clinical considerations. , 1992, Annual review of pharmacology and toxicology.
[7] A. Monro. The paradoxical lack of interspecies correlation between plasma concentrations and chemical carcinogenicity. , 1993, Regulatory toxicology and pharmacology : RTP.
[8] A. Monro,et al. What is an appropriate measure of exposure when testing drugs for carcinogenicity in rodents? , 1992, Toxicology and applied pharmacology.
[9] R. Shepard,et al. Pharmacokinetics of azithromycin in rats and dogs. , 1990, The Journal of antimicrobial chemotherapy.
[10] D W Nebert,et al. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. , 1991, DNA and cell biology.
[11] A. Monro. How useful are chronic (life-span) toxicology studies in rodents in identifying pharmaceuticals that pose a carcinogenic risk to humans? , 1993, Adverse drug reactions and toxicological reviews.
[12] S H Moolgavkar,et al. Mutation and cancer: a model for human carcinogenesis. , 1981, Journal of the National Cancer Institute.
[13] G Goodman,et al. Predicting the carcinogenicity of chemicals in humans from rodent bioassay data. , 1991, Environmental health perspectives.
[14] C. Haanen,et al. Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients , 2004, Cancer Chemotherapy and Pharmacology.
[15] J. Hopkins. Interpretation of negative epidemiological evidence for carcinogenicity: Edited by N.J. Wald & R. Doll. International Agency for Research on Cancer, Lyon, 1985. pp. vii + 232. £20.00. ISBN 0-19-723065-2 , 1987 .
[16] J. Haseman,et al. An examination of the association between maximum-tolerated dose and carcinogenicity in 326 long-term studies in rats and mice. , 1992, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[17] L. Bernstein,et al. Interspecies extrapolation in carcinogenesis: prediction between rats and mice. , 1989, Environmental health perspectives.
[18] J. Huff,et al. Scientific concepts, value, and significance of chemical carcinogenesis studies. , 1991, Annual review of pharmacology and toxicology.
[19] S. Ebara,et al. Repair of mucosal damage induced by ethanol in the rat stomach. Effects of concentration, exposure period and prostaglandins. , 1988, Digestion.
[20] H. Kao,et al. Site‐directed mutagenesis of a single residue changes the binding properties of the serotonin 5‐HT2 receptor from a human to a rat pharmacology , 1992, FEBS letters.
[21] K. Küpfmüller,et al. Quantitative Analyse der Krebsentstehung , 1948 .
[22] P. N. Lee,et al. Cancer and ageing in mice and men. , 1975, British Journal of Cancer.
[23] D. Smith,et al. Design of toxicokinetic studies. , 1990, Xenobiotica; the fate of foreign compounds in biological systems.
[24] J. Willerson,et al. Differences in myocardial α- and β-adrenergic receptor numbers in different species , 1983 .
[25] D. Langin,et al. Coexistence of three beta-adrenoceptor subtypes in white fat cells of various mammalian species. , 1991, European journal of pharmacology.
[26] M. Plummer,et al. International agency for research on cancer. , 2020, Archives of pathology.
[27] W. E. Lindup. Plasma protein binding of drugs: some basic and clinical aspects , 1987 .
[28] J. Palacios,et al. Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites , 1986, Brain Research.
[29] G Goodman,et al. Quantitative prediction of human cancer risk from rodent carcinogenic potencies: a closer look at the epidemiological evidence for some chemicals not definitively carcinogenic in humans. , 1991, Regulatory toxicology and pharmacology : RTP.
[30] H J Clewell,et al. Pharmacokinetics, biochemical mechanism and mutation accumulation: a comprehensive model of chemical carcinogenesis. , 1988, Toxicology letters.
[31] L. Ellwein,et al. Genetic errors, cell proliferation, and carcinogenesis. , 1991, Cancer research.
[32] M. J. Coon,et al. Cytochrome P450: progress and predictions , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[33] L. Chauvelot‐Moachon,et al. Effect of recombinant human interleukin-1 beta and tumor necrosis factor alpha on liver cytochrome P-450 and serum alpha-1-acid glycoprotein concentrations in the rat. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[34] L. Birnbaum. Pharmacokinetic basis of age-related changes in sensitivity to toxicants. , 1991, Annual review of pharmacology and toxicology.
[35] B S Pasternack,et al. Use of human data in quantitative risk assessment of carcinogens: impact on epidemiologic practice and the regulatory process. , 1992, Regulatory toxicology and pharmacology : RTP.
[36] J. Kremer,et al. Drug binding to human alpha-1-acid glycoprotein in health and disease. , 1988, Pharmacological reviews.
[37] B. Ames,et al. Chemical carcinogenesis: too many rodent carcinogens. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[38] D. Smith,et al. Role of metabolism and pharmacokinetic studies in the discovery of new drugs--present and future perspectives. , 1992, Xenobiotica; the fate of foreign compounds in biological systems.
[39] J. Tillement,et al. Diseases and Drug Protein Binding , 1978, Clinical pharmacokinetics.